Description
BSE lists 4,00,000 new equity shares of Novelix Pharmaceuticals Limited (Scrip Code: 536565) for trading effective March 9, 2026, issued on a preferential basis via conversion of warrants.
Summary
BSE has notified trading members that 4,00,000 new equity shares of Novelix Pharmaceuticals Limited (Scrip Code: 536565) are listed and permitted to trade on the Exchange effective Monday, March 9, 2026. These shares were issued to non-promoters on a preferential basis pursuant to conversion of warrants at an issue price of Rs. 20/- per share.
Key Points
- 4,00,000 equity shares of Rs. 10/- each issued at a premium of Rs. 10/- (issue price Rs. 20/-)
- Issued to non-promoters on a preferential basis via conversion of warrants
- Shares rank pari-passu with existing equity shares of the company
- ISIN: INE314I01036
- Distribution numbers: 17215001 to 17615000
- Date of allotment: January 19, 2026
Regulatory Changes
No regulatory changes. This is a standard listing notification for newly allotted securities.
Compliance Requirements
- Trading members are informed to note the listing of these new securities
- The 4,00,000 shares are subject to a lock-in period and cannot be freely traded until the lock-in expiry date
Important Dates
- Date of Allotment: January 19, 2026
- Trading Effective From: March 9, 2026 (Monday)
- Lock-in Expiry: September 30, 2026 (for all 4,00,000 shares, Dist. Nos. 17215001 to 17615000)
Impact Assessment
This listing adds 4,00,000 new equity shares to the tradeable float of Novelix Pharmaceuticals Limited. However, all newly listed shares are under lock-in until September 30, 2026, meaning they will not be available for open market trading immediately. The impact on liquidity and price discovery is minimal in the near term due to the lock-in restriction. This is a routine corporate action with low broader market significance.
Impact Justification
Routine listing of new shares from preferential allotment via warrant conversion for a small-cap pharma company; limited market-wide impact.